Roivant Sciences Ltd (ROIV)

$11.39 0.15 (1.33%)

16:00 EDT ROIV Stock Quote Delayed 30 Minutes

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026

By Yiannis Zourmpanos, InvestorPlace Contributor May 1, 2024

Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.

Why Is Roivant Sciences (ROIV) Stock Up Today?

3 Biotech Stocks That Analysts Are Drooling Over

3 Biotech Stocks for Getting Rich in 2023

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 3.69M

Day's Range $11.28 - $11.50

52-Week Range $8.25 - $13.24

Dividend & Yield N/A (N/A)

ROIV Stock Predictions, Articles, and Roivant Sciences Ltd News

From InvestorPlace
From the Web

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

By Josh Enomoto, InvestorPlace Contributor Mar 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Oct 21, 2021

Good morning, investor! We're getting right into the swing of things today with a look at the biggest pre-market stock movers for Thursday!

(NASDAQ:ROIV)

From Seeking Alpha Feb 13, 2024

Roivant Sciences surpasses expectations in Q3 financial results with a GAAP EPS of $6.03, beating estimates by $5.54, and revenue of $37.14M, surpassing...

Vivek Ramaswamy sells $33M Roivant stock (NASDAQ:ROIV)

From Seeking Alpha Jan 4, 2024

U.S. presidential candidate Vivek Ramaswamy sells over $33M worth of Roivant Sciences (ROIV) shares to finance his campaign. Read more here.

Ramaswamy Sells $33 Million Worth of Roivant Shares as Primaries Approach

From Bloomberg Jan 4, 2024

Vivek Ramaswamy sold about $33 million worth of shares in his biotech company Roivant Sciences Ltd., continuing to largely fund his presidential campaign with his own money.

Roivant slides on failed Phase 2 study for lupus drug candidate (ROIV)

From Seeking Alpha Nov 27, 2023

Roivant Sciences (ROIV) shares slid on news that a Phase 2 study of brepocitinib in the treatment of lupus failed to meet its primary endpoint. Read more here.

Roivant Sciences GAAP EPS of -$0.40 misses by $0.09, revenue of $37.1M beats by $9.98M (NASDAQ:ROIV)

From Seeking Alpha Nov 13, 2023

Roivant Sciences reports Q2 financial results with a GAAP EPS miss of $0.09, a non-GAAP net loss of $225.4M, and revenue that beats expectations by $9.98M.

3 No-Brainer Growth Stocks to Buy in October

From The Motley Fool Oct 1, 2023

These three top mid-cap stocks could be poised for a long-tailed growth spurt.

ADVERTISEMENT